FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that Reginald L. Hardy has been appointed as a director of the company to fill a vacancy on its Board of Directors. Mr. Hardy has extensive experience in the pharmaceutical and drug industries and currently serves as President of Concordia Pharmaceuticals, Inc., an anti-cancer drug development company that he founded.
